证券代码：300165 证券简称：ST天瑞 公告编号：2026-001 江苏天瑞仪器股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、实施其他风险警示的原因 公司于2024年12月6日收到中国证监会出具的《行政处罚事先告知书》，根据 《行政处罚事先告知书》认定的情况，公司涉及的违法违规行为触及《深圳证券 交易所创业板股票上市规则》第9.4条第（七）项规定的被实施其他风险警示情形， 公司股票于2024年12月10日起被实施其他风险警示，具体内容详见公司在巨潮资 讯网上披露的《关于公司股票交易被实施其他风险警示暨股票停复牌的提示性公 告》（公告编号：2024-074）。 二、采取的措施及进展情况 1、针对《行政处罚决定书》所涉事项，公司于2024年4月24日召开了第六 届董事会第七次会议和第六届监事会第五次会议，审议通过了《关于前期会计 差错更正及追溯调整的议案》，对2021年年报进行了会计差错更正及追溯调整， 并于2024年4月26日披露了《关于公司前期会计差错更正及追溯调整的公告》 ...

Core Viewpoint - ST Tianrui has resumed trading after terminating the planned change of control, with the stock closing at 4.60 yuan, reflecting a decline of 0.86% and a total market capitalization of 2.279 billion yuan [1]. Group 1 - The company announced the termination of the planned change of control due to a lack of consensus between the controlling shareholder and the counterparties involved [1]. - The decision to terminate the control change was made in a cautious manner, ensuring that it would not have a significant adverse impact on the company's operational performance and financial status [1]. - The company’s operations remain normal despite the termination of the control change plan [1]. Group 2 - The company applied to the Shenzhen Stock Exchange for the resumption of trading, which took effect on December 8, 2025 [2].

Core Viewpoint - The establishment of the Analysis Instrument Professional Committee under the China Nuclear Instrument Association marks a significant step towards integrating industry resources, promoting collaborative innovation, and strengthening standard leadership in the nuclear instrument sector [2][8][25]. Group 1: Event Overview - The founding conference of the Analysis Instrument Professional Committee took place on December 5, 2025, in Beijing, attended by industry professionals and experts [2][5]. - The meeting was hosted by Ma Jing, Chief Expert of China National Nuclear Corporation, with notable attendees including leaders from the National Defense Science and Technology Industry Bureau and the China Nuclear Instrument Association [2][8]. Group 2: Leadership and Structure - The conference included the election of the first council members, with Hou Liudong elected as the chairman and several vice-chairmen and directors appointed [13]. - The establishment of the committee was officially recognized with a plaque presentation by Xu Pengfei, representing the China Nuclear Instrument Association [13][25]. Group 3: Strategic Importance - The committee aims to address the increasing demands for precision, reliability, intelligence, and localization in analysis instruments due to the deepening application of nuclear technology across various sectors [25]. - There is a pressing need for breakthroughs in key technologies, construction of standard systems, and deep integration of production, learning, research, and application to enhance the overall capabilities of the industry and ensure the security of the industrial chain [25]. Group 4: Academic Contributions - The conference featured high-level reports from renowned experts in the field, covering topics such as single-cell immune mass spectrometry and key technologies for digitalization of material properties [20][21]. - These discussions provided significant academic insights and shared cutting-edge technologies relevant to the analysis instrument sector [20].

Group 1 - Century Huatong plans to change the use of 1.28 million repurchased shares from equity incentive plans to cancellation, reducing total share capital from 7.428 billion to 7.427 billion shares [2] - Wuliangye adjusts its 2025 investment plan, increasing the number of projects from 19 to 22 and changing the investment amount from 2.586 billion to 2.207 billion yuan [3] - Qingyue Technology is under investigation for suspected financial data fraud, with the possibility of forced delisting if found guilty [4] Group 2 - Kang Enbei's chairman and legal representative resigns due to work adjustments, along with another board member [5] - Tianshan Co. expects a tax payment of approximately 61.86 million yuan to impact its 2025 net profit [6] - Muyuan Foods reports a 20.43% year-on-year decline in November sales revenue from live pigs, totaling 9.39 billion yuan [7] Group 3 - GAC Group's November automobile sales decreased by 9.72% year-on-year, with total sales of 1.797 million vehicles [8] - Western Pastoral's fresh milk production in November increased by 6.3% month-on-month but decreased by 6.47% year-on-year [9] - Gemdale Group's November contracted area fell by 58.50% year-on-year, with a total contracted amount of 1.52 billion yuan [10] Group 4 - Zhenghong Technology reports November sales revenue of 4.5196 million yuan from live pigs, with a year-on-year decline of 21.83% [11] - Wens Foodstuff's November chicken sales reached 118 million birds, generating 3.324 billion yuan in revenue [12] - Meilixin's controlling shareholder plans to increase holdings by no less than 50 million yuan [13] Group 5 - Hongcheng Environment's subsidiary wins an 853 million yuan sewage treatment project [14] - Dongzhu Ecology wins a 397 million yuan environmental project [15] - Xindian Software secures a 54 million yuan project for digital community construction [16] Group 6 - China Chemical announces that its nylon new material project has reached full production [17] - Jiaojian Co. is in discussions regarding overdue payments related to financial products, clarifying that it bears no responsibility for these products [18] - Micron Biotech's product is included in the 2025 National Medical Insurance Directory [19] Group 7 - Yitian Intelligent plans to sell 600 smart computing machines for a total of 1.56 billion yuan [20] - First Venture's subsidiary receives an administrative penalty notice from Jiangsu Securities Regulatory Bureau [21] - China Insurance's vice president is under investigation for serious violations [22] Group 8 - Zhixiang Jintai's monoclonal antibody injection is included in the 2025 National Medical Insurance Directory [23] - Haichuang Pharmaceutical's drug is also included in the National Medical Insurance Directory [24] - Yuanli Co. plans to acquire 49% of Clarimex for 25.56 million USD [25] Group 9 - Betta Pharmaceuticals' products are included in the National Medical Insurance Directory [26] - Tianci Materials' controlling shareholder commits to not reducing holdings for six months [27] - Guanglian Aviation's actual controller has had a detention measure lifted [28] Group 10 - Annie Co. announces a share transfer agreement that will make Shengshi Tianan the controlling shareholder [29] - Double Star New Materials notes uncertainty regarding the sustainability of long-term price increases [30] - ST Tianrui terminates plans for a change in control and resumes trading [31] Group 11 - Guao Technology is planning a change in control, leading to a temporary suspension of its stock [32] - Guangqi Technology's subsidiary signs contracts worth 696 million yuan for the production of metamaterials [33] - Shuoshi Biotech's monkeypox virus detection kit is included in the WHO emergency use list [34]

Core Viewpoint - Jiangsu Tianrui Instrument Co., Ltd. has terminated the planning of a change in company control, which will not adversely affect its operations or future development strategy [2][3]. Group 1: Suspension of Trading - The company's stock (ST Tianrui, stock code: 300165) was suspended from trading starting December 1, 2025, due to the potential change in control involving the controlling shareholder and actual controller Liu Zhaogui [2]. - The suspension was implemented to ensure fair information disclosure and prevent abnormal fluctuations in the stock price during the planning phase of the control change [2]. Group 2: Termination of Control Change Planning - The termination of the control change planning was due to the lack of consensus on significant matters between the controlling shareholder and the transaction counterpart [3]. - The company confirmed that its operational status remains normal and that the termination will not have a significant adverse impact on its financial performance [3]. Group 3: Resumption of Trading - The company's stock is set to resume trading on December 8, 2025, following the termination of the control change planning [4]. - The company has expressed apologies for any inconvenience caused to investors due to the termination of the control change planning [4].

Core Viewpoint - ST Tianrui (300165) has announced the termination of its control change plan after only one week of consideration, with its stock set to resume trading on December 8 [2][4]. Group 1: Control Change Announcement - On December 7, ST Tianrui disclosed that it would terminate the planned change of control, leading to the resumption of its stock trading from December 8 [2][4]. - The stock was suspended from trading starting December 1 due to the potential change in control involving the company's controlling shareholder and actual controller, Liu Zhaogui [2][4]. Group 2: Reasons for Termination - The termination of the control change plan was due to a lack of agreement on significant matters between the controlling shareholder and the transaction counterpart [2][4]. - ST Tianrui stated that the termination would not have a significant adverse impact on the company's operational performance and financial condition [2][4].

Core Viewpoint - ST Tianrui (300165.SZ) announced the termination of the control change matter due to the lack of consensus between the controlling shareholder, actual controller, and the counterparty [1] Group 1 - The decision to terminate the control change was made based on a principle of prudence after discussions among the relevant parties [1] - The company has applied to the Shenzhen Stock Exchange for the resumption of its stock trading, which is set to resume on December 8, 2025 [1]

Group 1 - The core point of the article is that ST Tianrui (300165.SZ) announced the termination of its control rights change due to a lack of consensus between the controlling shareholder and the counterparty regarding significant matters related to the change [1] - The decision to terminate the control rights change was made based on a principle of prudence after discussions among the relevant parties [1] - The company has applied to the Shenzhen Stock Exchange for the resumption of its stock trading, which is set to resume on December 8, 2025, at the opening of the market [1]

Core Viewpoint - ST Tianrui (300165.SZ) announced that its controlling shareholder and actual controller, Liu Zhaogui, is planning a change in company control, which may lead to a change in the controlling shareholder and actual controller [1] Group 1: Control Change Announcement - The company has applied for a trading suspension starting from December 1, 2025, to ensure fair information disclosure and avoid abnormal stock price fluctuations [1] - The change in control is still in the planning stage and carries significant uncertainty [1] Group 2: Termination of Control Change - The controlling shareholder and actual controller have not reached an agreement with the counterparty regarding the significant matters related to the change in control [1] - The decision to terminate the control change planning was made based on mutual agreement among relevant parties, emphasizing a cautious approach [1] - The termination of this control change will not have a significant adverse impact on the company's operational performance and financial status [1] Group 3: Resumption of Trading - ST Tianrui's stock will resume trading on December 8, 2025, following the termination of the control change planning [1]

Core Viewpoint - ST Tianrui's planned change of control has been terminated after only one week of deliberation, with the company stating that the decision will not adversely affect its operational performance or financial status [1] Group 1: Control Change Announcement - On December 7, ST Tianrui announced the termination of its control change planning, with stock resuming trading on December 8 [1] - The company had previously suspended trading on December 1 due to the potential change in control involving its major shareholder and actual controller, Liu Zhaogui [1] Group 2: Reasons for Termination - The termination was due to a lack of consensus between the company's major shareholder, actual controller, and the transaction party regarding significant matters related to the control change [1] - ST Tianrui confirmed that its current operational conditions remain normal despite the termination of the control change planning [1]